Sagimet Biosciences Inc. Series A Common Stock (SGMT) support and resistance · rev $2.0M
Sagimet Biosciences Inc. Series A Common Stock (SGMT) is a biotechnology company listed on NASDAQ.
This page maps Sagimet Biosciences Inc. Series A Common Stock (SGMT) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported SGMT revenue for 2023-09-30 was $2.0M. Net income was -$6.4M. Revenue was up 0.0% from 2023-07-31 to 2023-09-30. SGMT currently screens at market cap $403.2M.
SGMT currently screens at market cap $403.2M. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new SGMT 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the SGMT quote page for the session range and the stock page for the full model.
Not investment advice.